|
|
Myeloma Minute
October 4, 2012
|
|
|
10.04.12 |
 |  |  |  | | October 4, 2012 |  |  |  |  |  |  | | |
 |
Myeloma Center Workshop at UNC/Duke
Chapel Hill, North Carolina
Friday, October 5, 2012
10 Steps to Better Nutrition: IMF Living Well Teleconference
Thursday, October 11, 2012
4 pm PACIFIC / 7 pm EASTERN
6th Annual Comedy Celebration Tickets on sale now
Saturday, October 27, 2012
Coach Rob's 7th Annual Benefit Bash & Golf Tournament
Orlando, Florida
October 28-29, 2012
Be Bold, Be Bald! Join the IMF team and wear a bald cap to honor those who battle cancer.
Friday, November 2, 2012
Sacramento Regional Community Workshop
Saturday, November 3, 2012
Myeloma Center Workshop at the Mayo Clinic Scottsdale, Arizona
Saturday, November 17, 2012
In Case You Missed It...
‘Getting to the Source: Acute and Chronic Pain’
IMF Teleconference Archive | |  | | Are Circulating Plasma Cell Levels a Helpful Marker of Early Active Disease? |  | | Although myeloma researchers have long agreed that certain patients are likelier to progress to active disease more rapidly than others, there has been no consensus on how to make that determination. Now the myeloma group at the Mayo Clinic in Rochester, MN, has identified a single determinant that can predict which patients have an 86% chance of developing active myeloma within two years. READ MORE | |
| | Patients Around the Globe Sought for Study of Carfilzomib and Velcade |  | | Physicians are currently looking for eligible patients with multiple myeloma to participate in a large study with approximately 200 sites around the world. The ENDEAVOR trial is evaluating progression-free survival in multiple myeloma patients with relapsing or progressing disease. The study compares carfilzomib (Kyprolis™) to bortezomib (Velcade®) to determine which drug can extend the time a patient lives without their disease worsening. READ MORE | |
| | Velcade Sub Q Approved in the European Union for Treatment of Myeloma |  | | The European Commission has approved the marketing authorization for the subcutaneous administration of Velcade (bortezomib). Last week’s ruling was based on data from a Phase III trial. "The trial results and approval of subcutaneous bortezomib builds on a wealth of existing data and experience with intravenous bortezomib, which already plays a vital role in managing multiple myeloma," said Professor Philippe Moreau, lead investigator on the trial and Head of Haematology at University Hospital Hotel-Dieu, Nantes, France. VELCADE RESOURCE PAGE | |
| | Have Questions About Kyprolis? We Have the Answers at Our New Resource Page |  | | The IMF Hotline is getting many calls about Kyprolis (carfilzomib), a next-generation proteasome inhibitor recently approved by the U.S. Food and Drug Administration. We welcome your calls and encourage everyone interested in learning more to visit the IMF Kyprolis Resource page on our website. LEARN MORE | |
| | Advocacy Team Passes 3,000 Advocates | | IMF’s advocacy team is proud to announce we have grown to more than 3,000 advocates since 2010. "We have come a long way in the past few years, successfully shaping policies to meet the needs of the myeloma community,” says Arin Assero, VP Global Advocacy. “But none of our victories would have been possible without our hardworking patients and caregivers who have given their time and endless dedication to our mission. We thank ALL of you for your fearlessness and determination to improve the lives of your fellow patients." Want to be part of the team? JOIN HERE | |  |
| | | | | | | | Join Our Mailing List |
| | | | | |
|
|
 related articles
|
|
back
print